Antisense Therapeutics Ltd (ASX: ANP) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Antisense Therapeutics Ltd. Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $117.02 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 668.71 million
Earnings per share -0.015
Dividend per share N/A
Year To Date Return -10.26%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Antisense Therapeutics Ltd (ASX: ANP)
Latest News

A sophisticated older lady with shoulder-length grey hair and glasses sits on her couch laughing while looking at her Neometals shares rising on her smartphone
Healthcare Shares

Here’s why the Antisense (ASX:ANP) share price is climbing 5% today

The Antisense Therapeutics Limited (ASX: ANP) share price is moving higher today. This upwards movement comes amid the company’s annual …

Read more »

Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory
Healthcare Shares

Antisense (ASX:ANP) share price accelerates 5% on FDA news

The Antisense Therapeutics Limited (ASX: ANP) share price is rising on the back of positive investor sentiment on Thursday. This comes after …

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Capital Raising

Antisense Therapeutics (ASX:ANP) share price tumbles 8% amid capital raise

Shares in Antisense Therapeutics Limited (ASX: ANP) are tumbling today following a heavily oversubscribed placement. At the time of writing, the Antisense share …

Read more »

Scientists in white coats look disappointed
Share Fallers

Here’s why the Antisense Therapeutics (ASX:ANP) share price has plummeted 19% on Monday

Shares in biopharmaceutical company Antisense Therapeutics Limited (ASX: ANP) made an abrupt downturn today and finished the session 18.64% lower …

Read more »

Female scientist working in laboratory for Race Oncology
Healthcare Shares

Why the Antisense (ASX:ANP) share price rocketed 16% today

The Antisense Therapeutics Limited (ASX: ANP) share price soared today without any news out of the company. It seems the market may …

Read more »

green arrow representing an increase in share price
Share Market News

Why the Antisense (ASX:ANP) share price finished 5% higher today

The Antisense Therapeutics Limited (ASX: ANP) share price finished the day higher today following a progress update. At market close, shares in the …

Read more »

Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares
Healthcare Shares

The Antisense (ASX:ANP) share price is surging 7% today. Here’s why

The Antisense Therapeutics Limited (ASX: ANP) share price is surging today after the company released a positive report regarding Phase …

Read more »

Share price soaring higher
Share Market News

Recent development sends the Antisense (ASX:ANP) share price soaring 45%

The Antisense Therapeutics Ltd (ASX: ANP) share price is storming high today. This comes as the biotech company made a …

Read more »

ANP ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Antisense Therapeutics Ltd

Antisense Therapeutics Ltd is a drug manufacturer. The company is engaged in research and development of novel antisense pharmaceuticals.

ANP Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
27 Jan 2022 $0.18 $0.00 0.00% 1,509,147 $0.17 $0.18 $0.17
25 Jan 2022 $0.18 $0.01 6.06% 1,681,389 $0.17 $0.18 $0.16
24 Jan 2022 $0.17 $-0.01 -5.71% 2,202,314 $0.18 $0.18 $0.17
21 Jan 2022 $0.18 $-0.01 -5.56% 778,328 $0.18 $0.18 $0.18
20 Jan 2022 $0.18 $-0.01 -5.41% 643,466 $0.19 $0.19 $0.18
19 Jan 2022 $0.19 $0.01 5.56% 2,001,468 $0.18 $0.19 $0.18
18 Jan 2022 $0.18 $-0.01 -5.41% 965,574 $0.19 $0.19 $0.18
17 Jan 2022 $0.19 $-0.01 -5.26% 715,001 $0.19 $0.19 $0.18
14 Jan 2022 $0.19 $0.01 5.41% 570,609 $0.19 $0.19 $0.19
13 Jan 2022 $0.19 $0.00 0.00% 931,538 $0.19 $0.19 $0.19
12 Jan 2022 $0.19 $-0.01 -5.26% 758,856 $0.20 $0.20 $0.19
11 Jan 2022 $0.19 $-0.01 -5.00% 512,578 $0.19 $0.20 $0.19
10 Jan 2022 $0.20 $0.01 5.26% 535,847 $0.19 $0.20 $0.19
07 Jan 2022 $0.19 $0.00 0.00% 297,035 $0.20 $0.20 $0.19
06 Jan 2022 $0.19 $-0.01 -5.00% 672,288 $0.21 $0.21 $0.19
05 Jan 2022 $0.20 $0.00 0.00% 598,876 $0.20 $0.21 $0.20
04 Jan 2022 $0.21 $0.01 5.13% 372,778 $0.20 $0.21 $0.20
31 Dec 2021 $0.20 $-0.01 -4.88% 192,143 $0.20 $0.21 $0.20
30 Dec 2021 $0.21 $0.00 0.00% 195,582 $0.21 $0.21 $0.20

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
22 Dec 2021 Mark Diamond Issued 235 $112,931
Rights issue.
22 Dec 2021 Mark Diamond Issued 470 $112,931
Issue of securities.
08 Nov 2021 Charmaine Gittleson Buy 133 $30,666
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Gary W Pace Non-Executive Director Nov 2015
Dr Pace has more than 40 years of experience in the development and commercialization of advanced technologies in biotechnology, pharmaceuticals, medical devices and the food industries. He has long-term experience with both multi-billion and small cap companies. He has held visiting academic positions at the Massachusetts Institute of Technology and the University of Queensland.
Mr Robert William Moses Non-Executive Director Oct 2001
Mr Moses has more than 40 years of experience in the pharmaceutical/ biotechnology industry. He was formerly Corporate Vice President of CSL Limited. Prior to joining CSL, Mr Moses was Managing Director of commercial law firm Freehills, Chairman and CEO of a NASDAQ listed medical service company, and Corporate Manager of New Business Development at ICI (now Orica). Mr Moses is also the former Non-Executive Chairman of TGR Biosciences Pty Ltd. Mr Moses also spent 17 years in various management roles at the multinational pharmaceutical company Eli Lilly.
Mr Mark P Diamond Chief Executive OfficerManaging Director Oct 2001
Mr Diamond has over 30 years of experience in the pharmaceutical and biotechnology industry. Before joining Antisense Therapeutics Limited as MD and CEO in 2001, Mr. Diamond was employed in the US as Director, Project Planning/ Business Development at Faulding Pharmaceuticals. Prior to this he held the positions of Senior Manager, Business Development and In-licensing within Faulding's European operation based in the UK and International Business Development Manager with Faulding in Australia.
Dr Ben Gil Price Non-Executive Director Oct 2021
--
Dr Charmaine Gittleson Non-Executive DirectorNon-Executive Chairman Mar 2021
Dr Gittleson has international experience as a pharmaceutical physician and enterprise leader in pharmaceutical drug development, governance and risk management gained during her 15-year tenure (2005-2020) with global specialty biotechnology company CSL Limited (ASX: CSL). During her time at CSL, Dr Gittleson had at various times accountability for clinical research, medical safety, medical and patient related ethics for development and on market programs, planning and implementation across multiple therapeutic and rare disease areas. Dr Gittleson held the key leadership roles of: Senior Director, Head Safety and Clinical Development (2006-2010) in Melbourne Australia; Vice President Clinical Strategy (2010-2013) and Senior Vice President Clinical Development (2013-2017) in Pennsylvania United States; and Chief Medical O cer in Melbourne from 2017 until her recent retirement from corporate roles in 2020.
Mr Phillip Hains Joint Company Secretary Nov 2006
-
Ms Alicia Mellors Joint Company Secretary Feb 2021
-
Nuket Desem Director Clinical & Regulatory Affairs
-
George Tachas Director Drug Discovery & Patents
-
Phillip Hains Joint Company Secretary
-
Alicia Mellors Joint Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 30,305,627 5.28%
BNP Paribas Nominees Pty Ltd ACF Clearstream 15,213,043 2.65%
Citicorp Nominees Pty Limited 14,306,353 2.49%
Altor Capital Management Pty Ltd <Altor Alpha Fund A/C> 11,611,771 2.02%
Citycastle Pty Ltd 10,564,222 1.84%
Esarad Holdings Pty Ltd 10,550,000 1.84%
Mr Dale Anthony Reed 10,300,000 1.79%
Mutual Investments Pty Ltd <Mitchell Family A/C> 10,270,602 1.79%
Jamplat Pty Ltd 10,200,000 1.78%
Mr Robert William Moses 9,090,201 1.58%
Mr Robertson Mclennan Mitchell & Mrs Karen Joy Mitchell 7,100,000 1.24%
Xcelerate Trading Pty Ltd <Xcelerate Trading A/C> 5,948,298 1.04%
Shared Office Services Pty Ltd <Philanne S/F A/C> 5,940,602 1.03%
Mr Jesse Hedley 5,201,283 0.91%
Mr Colin William Macleod & Mrs Linda Elizabeth Macleod <Macleod Super Fund A/C> 4,500,000 0.78%
Mr Mark Diamond 4,423,173 0.77%
Statemoor Pty Ltd <Peters Family A/C> 4,300,000 0.75%
Bayspec Pty Ltd 4,100,000 0.71%
Mr Glen Stephen Hanly 4,051,529 0.71%
Mr David Kenley 4,000,000 0.70%

Profile

since

Note